# Krystal completes VYJUVEK pricing negotiations in Germany and Italy

_Published Monday, November 2, 2026 at 4:18 PM EST · Science · Latest · Tier 2 — Notable_

Krystal Biotech has completed pricing negotiations in Germany and Italy for VYJUVEK, its gene therapy for dystrophic epidermolysis bullosa, FINVIZ reported. The company is targeting an Italian commercial launch in early 2027 as it expands European access to the treatment.

VYJUVEK has secured more than 760 reimbursement approvals in the United States. Discussions continue in other European countries and the United Kingdom. Krystal expects a Spanish pricing decision before the end of 2026, while a French decision is not anticipated before 2027. Launch timing depends on country-specific pricing and reimbursement processes.

## Sources

- [FINVIZ*Elite](https://elite.finviz.com/news/413243/krystal-biotech-shares-fall-37-despite-q3-earnings-beat-and-30-revenue-growth)

---
Canonical: https://techandbusiness.org/newswire/mNzLK25AlGgV7ypl3WPuKg
Published: 2026-11-02T21:18:35.049Z
Story chronology: 2026-11-02T08:42:00.000Z
Retrieved: 2026-11-02T23:28:42.423Z
Publisher: Tech & Business (techandbusiness.org)